Pfizer stock rises after Medicare flags Xeljanz for 2028 price talks — what investors watch next
Pfizer shares rose 2.3% to $26.50 in after-hours trading after Xeljanz was selected for Medicare price negotiations starting in 2028. CMS set a Feb. 28 deadline for drugmakers to opt in. Pfizer will release Q4 and full-year 2025 earnings on Feb. 3. Investors are watching for signals on pricing risk and market impact.